72 Endocrine and ovarian responses to combined estradiol benzoate-sulpiride in anestrous mares treated with kisspeptin

Bailey V, Sones J, Camp C, Oberhaus E

Journal of animal science1 Nov 2020

PMCIDPMC7697136PepBankPUB-90022850

Source link Source pageAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In anestrous mares given estradiol benzoate and sulpiride, prolactin responses tended to be greater with Kp10 than with saline (P = .09).
In plain wordsIn mares, prolactin tended to rise more with kisspeptin‑10 than with saline, but the difference was not statistically significant.
Peptide
Kisspeptin-10
Outcome
No significant changePlasma prolactin response to sulpiride
Study
horsen = 18
Anestrous mares given estradiol benzoate and sulpiride
Comparator
Saline pump (estradiol benzoate-sulpiride alone)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
50 mg/hour · subcutaneous · 7 daysAs given in this study (horse).
Source sentences
Summary
Prolactin responses tended to be greater (P = .09) in Kp10- treated mares compared to controls.
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract The objective of this study was to determine if incorporation of kisspeptin 10 (Kp10) into an estradiol benzoate (EB)-sulpiride treatment would result in greater endocrine responses, and a greater number of mares ovulating within 28 days of treatment compared to EB-sulpiride alone.
Summary · context
On day 1, mini osmotic pumps containing saline (n = 9) or Kp10 (50 mg/hour; n = 9) were inserted subcutaneously in the neck and remained for 7 days.
Report a problemFND-9002285001
02AnimalAnimal study (in vivo)Efficacy outcome
In anestrous mares, Kp10 did not change plasma LH during the first 24 hours after pump placement.
In plain wordsIn mares, kisspeptin‑10 did not change luteinizing hormone in the first 24 hours.
Peptide
Kisspeptin-10
Outcome
No significant changePlasma LH in the first 24 hours after pump placement
Study
horsen = 18
Anestrous mares given estradiol benzoate and sulpiride
Comparator
Saline pump (estradiol benzoate-sulpiride alone)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
50 mg/hour · subcutaneous · 7 daysAs given in this study (horse).
Source sentences
Summary
No differences were detected in plasma LH during the first 24 hours after pump placement
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract The objective of this study was to determine if incorporation of kisspeptin 10 (Kp10) into an estradiol benzoate (EB)-sulpiride treatment would result in greater endocrine responses, and a greater number of mares ovulating within 28 days of treatment compared to EB-sulpiride alone.
Summary · context
On day 1, mini osmotic pumps containing saline (n = 9) or Kp10 (50 mg/hour; n = 9) were inserted subcutaneously in the neck and remained for 7 days.
Report a problemFND-9002285002
03AnimalAnimal study (in vivo)Efficacy outcome
In anestrous mares given estradiol benzoate and sulpiride, plasma LH was greater with Kp10 than with saline from day 7 to day 21.
In plain wordsIn mares, luteinizing hormone was higher with kisspeptin‑10 than with saline from day 7 to day 21.
Peptide
Kisspeptin-10
Outcome
IncreasePlasma LH from day 7 to day 21
Study
horsen = 18
Anestrous mares given estradiol benzoate and sulpiride
Comparator
Saline pump (estradiol benzoate-sulpiride alone)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
50 mg/hour · subcutaneous · 7 daysAs given in this study (horse).
Source sentences
Summary
LH increased in all mares beginning 5 days after sulpiride and were greater (P < .05) in Kp10-mares from day 7 to day 21
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract The objective of this study was to determine if incorporation of kisspeptin 10 (Kp10) into an estradiol benzoate (EB)-sulpiride treatment would result in greater endocrine responses, and a greater number of mares ovulating within 28 days of treatment compared to EB-sulpiride alone.
Summary · context
On day 1, mini osmotic pumps containing saline (n = 9) or Kp10 (50 mg/hour; n = 9) were inserted subcutaneously in the neck and remained for 7 days.
Report a problemFND-9002285003
04AnimalAnimal study (in vivo)Efficacy outcome
In anestrous mares given estradiol benzoate and sulpiride, ovulation dates did not differ between Kp10-treated and control mares.
In plain wordsIn mares, kisspeptin‑10 did not change when ovulation happened compared with saline.
Peptide
Kisspeptin-10
Outcome
No significant changeOvulation dates
Study
horsen = 18
Anestrous mares given estradiol benzoate and sulpiride
Comparator
Saline pump (estradiol benzoate-sulpiride alone)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
50 mg/hour · subcutaneous · 7 daysAs given in this study (horse).
Source sentences
Summary
Eleven of 18 (61%) mares ovulated within 18 days of sulpiride treatment; however, no differences in ovulation dates were detected between Kp10 treated- and control- mares.
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract The objective of this study was to determine if incorporation of kisspeptin 10 (Kp10) into an estradiol benzoate (EB)-sulpiride treatment would result in greater endocrine responses, and a greater number of mares ovulating within 28 days of treatment compared to EB-sulpiride alone.
Summary · context
On day 1, mini osmotic pumps containing saline (n = 9) or Kp10 (50 mg/hour; n = 9) were inserted subcutaneously in the neck and remained for 7 days.
Report a problemFND-9002285004
05AnimalAnimal study (in vivo)Efficacy outcome
In anestrous mares, Kp10 did not change plasma progesterone during the first 5 days after ovulation.
In plain wordsIn mares, kisspeptin‑10 did not change progesterone in the first 5 days after ovulation.
Peptide
Kisspeptin-10
Outcome
No significant changePlasma progesterone in the first 5 days after ovulation
Study
horsen = 18
Anestrous mares given estradiol benzoate and sulpiride
Comparator
Saline pump (estradiol benzoate-sulpiride alone)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
50 mg/hour · subcutaneous · 7 daysAs given in this study (horse).
Source sentences
Summary
No differences were detected in plasma progesterone during the first 5 days post ovulation.
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract The objective of this study was to determine if incorporation of kisspeptin 10 (Kp10) into an estradiol benzoate (EB)-sulpiride treatment would result in greater endocrine responses, and a greater number of mares ovulating within 28 days of treatment compared to EB-sulpiride alone.
Summary · context
On day 1, mini osmotic pumps containing saline (n = 9) or Kp10 (50 mg/hour; n = 9) were inserted subcutaneously in the neck and remained for 7 days.
Report a problemFND-9002285005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Abstract

PepBank is a research reference. Talk to a doctor before you use any peptide.